The MightySat Fingertip Pulse Oximeter is reportedly the first pulse oximeter available without a prescription.
Earlier this week, Masimo announced the FDA clearance of the MightySat Fingertip Pulse Oximeter, representing the first FDA-cleared fingertip pulse oximeter for over-the-counter (OTC) sale directly to consumers without a prescription. According to the company, the new device is equipped with Masimo SET pulse oximetry technology, known for accuracy and reliability in hospitals, addressing a significant gap in the market for dependable home-use medical devices.
The device is designed to deliver precise oxygen saturation (SpO2) and pulse rate (PR) measurements regardless of the patient's skin color or low perfusion, addressing a significant gap in the market for dependable home-use medical devices. This is the only pulse oximeter sold directly consumers cleared by the FDA for medical use, according to Masimo.1
“Until now, consumers and even healthcare providers had no way of knowing what pulse oximeter they could trust to use at home. On the internet and even in drug stores, they are inundated with a myriad of products that are unreliable, with misleading advertisements about their abilities to provide accurate measurements of oxygen saturation and pulse rate,” said Joe Kiani, founder, CEO, Masimo, in a company press release. “This clearance of MightySat Medical for consumers eliminates the confusion, placing an FDA-cleared, accurate, reliable, and revolutionary SET pulse oximeter, with technology that hospitals have been using for more than 25 years, directly into their hands. Healthcare providers can also now be confident when referring their patients to get MightySat Medical knowing that it has actually been cleared by the FDA as an OTC medical pulse oximeter.”
This clearance comes amid the FDA resuming discussions to address how to provide higher accuracy for people of color using pulse oximeters. According to an article by Axios, current technology can misread the level of oxygen saturation in patients with darker skin, with researchers suggesting software updates to eliminate any discrepancies. Despite the agency having no obligation to make any changes, it’s facing a considerable amount of pressure to act on the issue.2
"We shouldn't putz around. It's as important in people with respiratory diseases as blood glucose for diabetics," Meir Kryger, a retired sleep researcher and professor emeritus Yale School of Medicine, told Axios. “It's an important measurement, and the doctor or the consumer who's told to get one of these needs to have the confidence that the device is actually accurate."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.